Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H23N5O6S |
| Molecular Weight | 521.545 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)C3=CN=C4C=CC=NC4=C3O)C5=CC=CC=C5)C(=O)N2[C@H]1C(O)=O
InChI
InChIKey=XMQVYNAURODYCQ-SLFBBCNNSA-N
InChI=1S/C25H23N5O6S/c1-25(2)19(24(35)36)30-22(34)17(23(30)37-25)29-21(33)15(12-7-4-3-5-8-12)28-20(32)13-11-27-14-9-6-10-26-16(14)18(13)31/h3-11,15,17,19,23H,1-2H3,(H,27,31)(H,28,32)(H,29,33)(H,35,36)/t15-,17-,19+,23-/m1/s1
Apalcillin is a naphthydridine derivative of ampicillin. Apalcillin has a broad spectrum of antibacterial activity that is very similar to that of piperacillin, except that apalcillin is significantly more active against Pseudomonas aeruginosa and Acinetobacter spp. Against Acinetobacter spp., apalcillin is uniquely active, compared to the other penicillins and comparison drugs. Strains producing high amounts of β-lactamases do become resistant to apalcillin. PAH (p-aminohippurate) clearance was significantly decreased during apalcillin infusion. Apalcillin appeared to compete with PAH for proximal tubular secretion but induced no further renal dysfunction.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1500
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m1980
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
PRIMARY | Merck Index | ||
|
C76217
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
PRIMARY | |||
|
51691
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
PRIMARY | |||
|
SUB05535MIG
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
PRIMARY | |||
|
CHEMBL3306902
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
PRIMARY | |||
|
227
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
PRIMARY | |||
|
4422
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
PRIMARY | |||
|
3373RT9U7A
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
PRIMARY | |||
|
DTXSID601016509
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
PRIMARY | |||
|
C012122
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
PRIMARY | |||
|
100000086956
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
PRIMARY | |||
|
6602341
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
PRIMARY | |||
|
63469-19-2
Created by
admin on Mon Mar 31 18:30:59 GMT 2025 , Edited by admin on Mon Mar 31 18:30:59 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
